Shanghai Fosun Pharmaceutical Group Co Ltd, a prominent player in the healthcare sector, has been making significant strides in the pharmaceutical industry. Based in Shanghai, China, the company has carved out a niche for itself by focusing on a diverse range of pharmaceutical products. These include genetic medicines, Chinese traditional medicines, diagnostic products, reagents, and medical equipment. As of May 7, 2026, the company’s shares are traded on the Hong Kong Stock Exchange, reflecting its international reach and investor confidence.
The company’s financial performance has been noteworthy, with a close price of 18.91 HKD on May 5, 2026. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 29 HKD on September 15, 2025, and a low of 13.72 HKD on May 11, 2025. These movements highlight the dynamic nature of the pharmaceutical market and the company’s resilience in navigating these changes.
With a market capitalization of 51,085,312,000 HKD, Shanghai Fosun Pharmaceutical Group stands as a significant entity within the healthcare sector. The company’s price-to-earnings ratio of 13.09 suggests a balanced valuation, indicating investor confidence in its growth prospects and operational efficiency.
Founded in 1998, Shanghai Fosun Pharmaceutical Group has grown from its initial public offering on the Shanghai Stock Exchange to become a key player in the global pharmaceutical landscape. The company’s commitment to innovation and quality is evident in its diverse product offerings, which cater to a wide range of medical needs. By integrating modern pharmaceutical practices with traditional Chinese medicine, the company has positioned itself uniquely in the market.
For those interested in learning more about Shanghai Fosun Pharmaceutical Group’s offerings and initiatives, further information is available on their website at www.fosunpharma.com . The company’s dedication to advancing healthcare solutions continues to drive its success and influence in the industry.
